Pro Share Advisors LLC Catalyst Pharmaceuticals, Inc. Transaction History

Pro Share Advisors LLC

$36.5 Billion
Q2 2024

A detailed history of Pro Share Advisors LLC transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Pro Share Advisors LLC holds 17,162 shares of CPRX stock, worth $340,150. This represents 0.0% of its overall portfolio holdings.

Number of Shares

17,162

Previous 22,457 23.58%

Holding current value

$340,150

Previous $357,000 25.77%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$14.68 - $16.92 $77,730 - $89,591	-5,295 Reduced 23.58%	17,162 $265,000
Q1 2024 May 08, 2024	BUY	$13.18 - $17.11 $47,632 - $61,835	3,614 Added 19.18%	22,457 $357,000
Q4 2023 Feb 14, 2024	BUY	$11.78 - $17.29 $41,983 - $61,621	3,564 Added 23.33%	18,843 $316,000
Q3 2023 Nov 13, 2023	BUY	$11.69 - $15.02 $2,244 - $2,883	192 Added 1.27%	15,279 $178,000
Q2 2023 Aug 10, 2023	BUY	$11.5 - $18.08 $12,144 - $19,092	1,056 Added 7.53%	15,087 $202,000
Q1 2023 May 11, 2023	SELL	$14.34 - $21.05 $17,824 - $26,165	-1,243 Reduced 8.14%	14,031 $232,000
Q4 2022 Feb 02, 2023	BUY	$12.25 - $19.5 $24,830 - $39,526	2,027 Added 15.3%	15,274 $284,000
Q3 2022 Nov 04, 2022	BUY	$7.06 - $15.52 $17,537 - $38,551	2,484 Added 23.08%	13,247 $169,000
Q2 2022 Aug 01, 2022	SELL	$6.23 - $8.57 $46,382 - $63,803	-7,445 Reduced 40.89%	10,763 $75,000
Q1 2022 May 10, 2022	SELL	$5.31 - $8.31 $15,972 - $24,996	-3,008 Reduced 14.18%	18,208 $151,000
Q4 2021 Feb 08, 2022	BUY	$5.21 - $7.45 $45,712 - $65,366	8,774 Added 70.52%	21,216 $143,000
Q3 2021 Nov 12, 2021	SELL	$4.85 - $6.04 $61,827 - $76,997	-12,748 Reduced 50.61%	12,442 $66,000
Q2 2021 Aug 13, 2021	SELL	$4.29 - $6.05 $3,187 - $4,495	-743 Reduced 2.87%	25,190 $145,000
Q1 2021 May 14, 2021	BUY	$3.45 - $4.69 $15,273 - $20,762	4,427 Added 20.58%	25,933 $120,000
Q4 2020 Feb 09, 2021	BUY	$2.97 - $3.83 $28,529 - $36,790	9,606 Added 80.72%	21,506 $72,000
Q3 2020 Nov 13, 2020	SELL	$2.97 - $5.08 $3,834 - $6,558	-1,291 Reduced 9.79%	11,900 $35,000
Q2 2020 Aug 03, 2020	BUY	$3.48 - $5.05 $45,904 - $66,614	13,191 New	13,191 $61,000
Q1 2020 May 15, 2020	SELL	$2.61 - $5.21 $34,133 - $68,136	-13,078 Closed	0 $0
Q4 2019 Feb 12, 2020	BUY	$3.67 - $5.7 $7,666 - $11,907	2,089 Added 19.01%	13,078 $49,000
Q3 2019 Nov 12, 2019	BUY	$3.89 - $7.43 $3,014 - $5,758	775 Added 7.59%	10,989 $58,000
Q2 2019 Aug 13, 2019	SELL	$2.7 - $6.11 $737 - $1,668	-273 Reduced 2.6%	10,214 $39,000
Q1 2019 May 15, 2019	BUY	$2.11 - $5.33 $687 - $1,737	326 Added 3.21%	10,487 $53,000
Q4 2018 Feb 14, 2019	SELL	$1.92 - $3.62 $3,148 - $5,936	-1,640 Reduced 13.9%	10,161 $20,000
Q3 2018 Nov 14, 2018	SELL	$2.81 - $3.78 $2,540 - $3,417	-904 Reduced 7.12%	11,801 $45,000
Q2 2018 Aug 13, 2018	BUY	$2.26 - $3.84 $3,437 - $5,840	1,521 Added 13.6%	12,705 $40,000
Q1 2018 May 14, 2018	BUY	$2.39 - $4.01 $1,347 - $2,261	564 Added 5.31%	11,184 $27,000
Q4 2017 Feb 14, 2018	BUY	$2.51 - $4.4 $26,656 - $46,728	10,620	10,620 $42,000

Others Institutions Holding CPRX

# of Institutions

285

Shares Held

96.6M

Call Options Held

29.2K

Put Options Held

20.5K

View Full List

About CATALYST PHARMACEUTICALS, INC.

Ticker CPRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 102,820,000
Market Cap $2.04B
Description
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...

More about CPRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Share Advisors LLC with notifications on news.

Account

Pro Share Advisors LLC Catalyst Pharmaceuticals, Inc. Transaction History